Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells

British Journal of Cancer

Volumn 86, Issue 7, 2002, Pages 1104-1109

  Huang, G C ^a   Hobbs, S ^b   Walton, M ^b   Epstein, R J ^c,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Apoptosis; ErbB2; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; KNOCKOUT GENE; ONCOGENE MYC; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; DISEASE PROGRESSION; FEMALE; GENES, ERBB-2; HUMANS; KINETICS; LIGANDS; PHENOTYPE; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 85047700153     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600219     Document Type: Article

References (68)

1. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells
2. Suppression of human colorectal carcinoma cell growth by wild-type p53
3. p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons
4. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src
5. All erbB receptors other than the epidermal growth factor receptor are endocytosis impaired
6. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway
7. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
8. Extensive apoptosis in ductal carcinoma in situ of the breast
9. p53 gene mutations and steroid receptor status in breast cancer: Clinicopathologic correlations and prognostic assessment
10. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene
11. p53 mutation as a genetic trait of typical medullary breast carcinoma
12. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
13. Differential activation of transcription factors induced by calcium response amplitude and duration
14. p53 mutation and tamoxifen resistance in breast cancer
15. Modulation of a 175-kDa c-neu receptor isoform in G8/DHFR cells by serum starvation
16. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor
17. Induction of apoptosis in fibroblasts by c-myc protein
18. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis
19. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor receptors, has an amplified EGF receptor gene and is growth inhibited by EGF
20. A comprehensive system to explore p53 mutations
21. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells
22. Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity
23. Reduced ability of transforming growth factor-alpha to induce EGF receptor heterodimerization and downregulation suggests a mechanism of oncogenic synergy with ErbB2
24. Down-regulation of bcl-2 by p53 in breast cancer cells
25. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines
26. The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-neu and its abrogation by glucocorticoids
27. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer
28. Overexpression of ErbB2 impairs downregulation of epidermal growth factor receptors via a post-transcriptional mechanism
29. Proxy activation of ErbB2 by heterologous ligands suggests a heterotetrameric mechanism of receptor tyrosine kinase interaction
30. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB
31. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells
32. Role of mitogen-activated protein kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line
33. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-HER2 monoclonal antibodies
34. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
35. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer
36. Neu/ERBB2 cooperates with p53-172H during mammary tumourigenesis in transgenic mice
37. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast
38. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
39. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells
40. Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice
41. Direct activation of the serine/threonine kinase activity of raf-1 through tyrosine phosphorylation by the PDGF receptor
42. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase
43. p53 modulation of anchorage independent growth and experimental metastasis
44. Adjacent carboxyterminal tyrosine phosphorylation events identify functionally distinct ErbB2 receptor subsets: Implications for molecular diagnostics
45. Transforming growth factor-alpha short-circuits downregulation of the epidermal growth factor receptor
46. Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state-specific antibodies
47. Association of ErbB2 Ser-1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer
48. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways
49. c-ErbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis
50. Epidermal growth factor stimulates DNA synthesis while inhibiting cell multiplication of A431 carcinoma cells
51. p53-mutant clones and field defects in Barrett's esophagus
52. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway
53. Epidermal growth factor receptors and oestrogen receptors in human breast cancer
54. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
55. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage
56. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired
57. HER2 and growth inhibition of cells with HER2/neu gene amplification
58. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
59. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells
60. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases
61. Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53
62. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma
63. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance
64. Cip1
65. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2
66. Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells
67. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles
68. A temperature-sensitive mutant of human p53